Details of how Raf inhibitors interact with their protein targets enable modeling of how drug resistance develops. Together with other biochemical data, computational models predict how to combine inhibitors for more effective ca…
Pancreatic cancer cells activate stellate cells in their microenvironment, causing them to secrete lipid molecules. Some of these molecules are converted to a potent signaling lipid, which increases cancer growth. from RAS Dia…
Cancers driven by mutant RAS genes show increased autophagy. Unexpectedly, inhibition of signaling through mutant RAS further increases autophagy. Dual inhibition of MAPK signaling and autophagy inhibits pancreatic cancer. fro…
Recent discoveries and new approaches are chipping away at the cancers caused by mutant RAS genes. For the first time drugs that target RAS directly are in human clinical trials. from RAS Dialogue https://ift.tt/2NHeOSF
Signaling downstream of RAS is subject to many levels of regulation. Inhibiting MEK seems to re-wire that regulation so that inhibitors of RAF kinases are more effective against cells driven by mutant KRAS. from RAS Dialogue h…
Mutated RAS genes are an important cause of colorectal cancers, and play a role in resistance to current drug therapies. Remarkably, patients whose cancer is progressing despite treatment often have multiple different RAS mutatio…
Cancers driven by mutant KRAS are difficult to treat. Combining genetic screens with drugs that work downstream of mutant KRAS reveals cellular adaptations to uncontrolled growth that may be targeted. from RAS Dialogue https:/…
